CoLucid Pharmaceuticals Company Profile (NASDAQ:CLCD)

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals logoCoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLCD
  • CUSIP:
Key Metrics:
  • Previous Close: $8.65
  • 50 Day Moving Average: $8.78
  • 200 Day Moving Average: $7.14
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.98
  • P/E Growth: 0.00
  • Market Cap: $131.87M
  • Outstanding Shares: 15,334,000
  • Beta: 1.85
Additional Links:
Companies Related to CoLucid Pharmaceuticals:

Analyst Ratings

Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (155.81% upside)

Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
DateFirmActionRatingPrice TargetDetails
11/10/2015William BlairInitiated CoverageBuy$22.00View Rating Details
6/1/2015Ladenburg ThalmannInitiated CoverageBuy$20.00View Rating Details
6/1/2015Stifel NicolausInitiated CoverageBuy$15.00 -> $15.00View Rating Details
6/1/2015Piper Jaffray Cos.Initiated CoverageOverweight$21.00View Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/10/2016Q2($0.84)($1.06)ViewN/AView Earnings Details
5/11/2016Q1($0.73)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.63)($0.59)ViewN/AView Earnings Details
8/12/2015($0.35)($1.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Current Year EPS Consensus Estimate: $-4.01 EPS
Next Year EPS Consensus Estimate: $-2.89 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.92)($0.92)($0.92)
Q4 20161($0.97)($0.97)($0.97)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016Raymond SkwierczynskiInsiderSell508$8.41$4,272.28View SEC Filing  
8/10/2016Raymond SkwierczynskiInsiderSell508$8.30$4,216.40View SEC Filing  
8/5/2016Thomas P MathersCEOSell1,502$8.31$12,481.62View SEC Filing  
8/3/2016Domain Partners Vi, L.P.Major ShareholderSell153,028$8.45$1,293,086.60View SEC Filing  
7/29/2016Raymond SkwierczynskiInsiderSell508$9.09$4,617.72View SEC Filing  
7/20/2016Raymond SkwierczynskiInsiderSell508$8.97$4,556.76View SEC Filing  
7/11/2016Raymond SkwierczynskiInsiderSell508$9.10$4,622.80View SEC Filing  
6/30/2016Raymond SkwierczynskiInsiderSell516$7.01$3,617.16View SEC Filing  
6/20/2016Raymond SkwierczynskiInsiderSell1,008$6.80$6,854.40View SEC Filing  
6/6/2016Thomas P MathersCEOSell1,502$7.25$10,889.50View SEC Filing  
4/28/2016Vi Associates L.P. DpMajor ShareholderSell235$6.96$1,635.60View SEC Filing  
8/25/2015Thomas P MathersCEOBuy7,500$7.10$53,250.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy1,300,000$10.00$13,000,000.00View SEC Filing  
5/11/2015Arthur M PappasDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateHeadline
marketexclusive.com logoTwo Catlaysts To Watch Early September In Biotech: Bioline RX Ltd (NASDAQ:BLRX) and CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) (NASDAQ:CLCD)
marketexclusive.com - August 25 at 9:10 AM
finance.yahoo.com logoKing Fish Media Announces Website Launch for CoLucid Pharmaceuticals (NASDAQ:CLCD)
finance.yahoo.com - August 18 at 11:21 AM
cnbc.com logoCoLucid Pharmaceuticals posts 2Q loss (NASDAQ:CLCD)
www.cnbc.com - August 10 at 10:28 PM
publicnow.com logoCoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights (NASDAQ:CLCD)
www.publicnow.com - August 10 at 4:19 PM
finance.yahoo.com logoCoLucid Pharmaceuticals Hosting Key Opinion Leader Meeting in New York City (NASDAQ:CLCD)
finance.yahoo.com - June 22 at 4:01 PM
capitalcube.com logoCoLucid Pharmaceuticals, Inc. :CLCD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:CLCD)
www.capitalcube.com - June 8 at 6:04 PM
publicnow.com logoCoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine (NASDAQ:CLCD)
www.publicnow.com - June 7 at 8:48 AM
finance.yahoo.com logoCoLucid Pharmaceuticals to Participate at the Jefferies 2016 Healthcare Conference (NASDAQ:CLCD)
finance.yahoo.com - June 2 at 8:58 AM
finance.yahoo.com logoCoLucid Pharmaceuticals (CLCD) in Focus: Stock Rises 11.1% (NASDAQ:CLCD)
finance.yahoo.com - June 1 at 8:15 AM
News IconStock Rating Review for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Wall Street Hints and News (NASDAQ:CLCD)
hintsnewsnetwork.com - May 27 at 1:20 PM
News IconTarget Check and Stock Performance Recap CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Wall Street Hints and News (NASDAQ:CLCD)
hintsnewsnetwork.com - May 26 at 12:25 PM
finance.yahoo.com logoCoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine (NASDAQ:CLCD)
finance.yahoo.com - May 19 at 12:47 PM
sg.finance.yahoo.com logoCoLucid Pharmaceuticals posts 1Q loss (NASDAQ:CLCD)
sg.finance.yahoo.com - May 11 at 5:42 PM
publicnow.com logoCoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights (NASDAQ:CLCD)
www.publicnow.com - May 11 at 5:17 PM
News IconColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Sellers Increased By 3.68% Their Shorts - RiversideGazette.com (NASDAQ:CLCD)
www.riversidegazette.com - April 3 at 2:56 PM
finance.yahoo.com logoCOLUCID PHARMACEUTICALS, INC. Financials (NASDAQ:CLCD)
finance.yahoo.com - March 29 at 1:04 PM
biz.yahoo.com logoCOLUCID PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report (NASDAQ:CLCD)
biz.yahoo.com - March 24 at 6:07 AM
News IconCoLucid Pharmaceuticals, Inc. (CLCD): Analyst Targets For The Coming Week - Share Trading News (NASDAQ:CLCD)
www.sharetrading.news - March 20 at 2:43 PM
News IconChanges To Broker Targets On CoLucid Pharmaceuticals, Inc. (CLCD) - Share Trading News (NASDAQ:CLCD)
www.sharetrading.news - March 15 at 2:46 PM
finance.yahoo.com logoCoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors (NASDAQ:CLCD)
finance.yahoo.com - March 15 at 8:00 AM
News IconCoLucid Pharmaceuticals, Inc. (CLCD) Broker Updates - Risers & Fallers (NASDAQ:CLCD)
www.risersandfallers.com - March 11 at 2:22 PM
News IconAverage Rating Update on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Business Standard Tribune (NASDAQ:CLCD)
www.standardtrib.com - March 10 at 2:33 PM
wallstreet.org logoCoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Analyst Rating & Update - WallStreet.org (NASDAQ:CLCD)
www.wallstreet.org - March 9 at 2:38 PM
News IconCoLucid Pharmaceuticals, Inc. (CLCD) Updated Price Targets - Share Trading News (NASDAQ:CLCD)
www.sharetrading.news - March 9 at 2:38 PM
News IconUpdated Price Targets On CoLucid Pharmaceuticals, Inc. (CLCD) - Risers & Fallers (NASDAQ:CLCD)
www.risersandfallers.com - March 8 at 2:33 PM
News IconColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Increased By 7.44% - RiversideGazette.com (NASDAQ:CLCD)
www.riversidegazette.com - March 3 at 2:21 PM
finance.yahoo.com logoCoLucid Pharmaceuticals to Present Corporate Overview at the Cowen & Company 36th Annual Health Care Conference (NASDAQ:CLCD)
finance.yahoo.com - March 3 at 8:00 AM
sg.finance.yahoo.com logoCoLucid Pharmaceuticals posts 4Q loss (NASDAQ:CLCD)
sg.finance.yahoo.com - March 2 at 5:27 PM
finance.yahoo.com logoCoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate Highlights (NASDAQ:CLCD)
finance.yahoo.com - March 2 at 4:23 PM
News IconStock Moving Upward: CoLucid Pharmaceuticals, Inc.( NASDAQ:CLCD ) - Stock Caller (NASDAQ:CLCD)
www.stockcaller.com - March 2 at 1:59 PM
wallstreet.org logoStock Rating & Analysis on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - WallStreet.org (NASDAQ:CLCD)
www.wallstreet.org - March 2 at 1:59 PM
News IconCoLucid Pharmaceuticals, Inc. (CLCD) New Analyst Ratings - Share Trading News (NASDAQ:CLCD)
www.sharetrading.news - March 1 at 2:17 PM
finance.yahoo.com logo8:02 am CoLucid Pharmaceuticals receives a Special Protocol Agreement for second phase 3 trial from US FDA (NASDAQ:CLCD)
finance.yahoo.com - March 1 at 8:02 AM
finance.yahoo.com logoCoLucid Pharmaceuticals Announces Special Protocol Agreement for SPARTAN (NASDAQ:CLCD)
finance.yahoo.com - March 1 at 8:00 AM
News IconPrice Target Update On CoLucid Pharmaceuticals, Inc. (CLCD) - Risers & Fallers (NASDAQ:CLCD)
www.risersandfallers.com - February 29 at 2:18 PM
News IconWhat to Expect from CoLucid Pharmaceuticals Inc (CLCD) EPS? - OctaFinance.com (NASDAQ:CLCD)
www.octafinance.com - February 29 at 2:18 PM
benzinga.com logoCoLucid Pharma Reports Confirmatory Support for Non-Vasoconstrictive Mechanism of ACtion for Lasmiditan - Benzinga (NASDAQ:CLCD)
www.benzinga.com - February 24 at 1:52 PM
benzinga.com logoCoLucid Pharma Reports Confirmatory Support for Non-Vasoconstrictive Mechanism of ACtion for Lasmiditan (NASDAQ:CLCD)
www.benzinga.com - February 23 at 1:24 PM
4-traders.com logoCoLucid Pharmaceuticals : Reports Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan (NASDAQ:CLCD)
www.4-traders.com - February 23 at 1:24 PM
finance.yahoo.com logoCoLucid Pharmaceuticals Announces Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan (NASDAQ:CLCD)
finance.yahoo.com - February 23 at 8:12 AM
News IconColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Decreased By 1.41% - Franklin Independent (NASDAQ:CLCD)
www.franklinindependent.com - February 20 at 1:38 PM
News IconColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Decreased By 1.41% - fdanewsalert.com (NASDAQ:CLCD)
www.fdanewsalert.com - February 13 at 1:34 PM
finance.yahoo.com logoCoLucid Pharmaceuticals (CLCD) in Focus: Stock Up 9.9% (NASDAQ:CLCD)
finance.yahoo.com - February 12 at 8:45 AM
News IconRecent Broker Updates On CoLucid Pharmaceuticals, Inc. (CLCD) - Risers & Fallers (NASDAQ:CLCD)
www.risersandfallers.com - February 11 at 1:38 PM
News IconColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Shorted Shares Increased 6.9% After Market Selling - fdanewsalert.com (NASDAQ:CLCD)
www.fdanewsalert.com - February 9 at 1:19 PM
wallstreet.org logoAnalysts Forecast Higher CoLucid Pharmaceuticals Inc (CLCD) Earnings Per Share - WallStreet.org (NASDAQ:CLCD)
www.wallstreet.org - February 9 at 1:19 PM
nasdaq.com logoCoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) to Ring The Nasdaq Stock Market Closing Bell - Nasdaq (NASDAQ:CLCD)
www.nasdaq.com - February 5 at 1:50 PM
finance.yahoo.com logoCoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:CLCD)
finance.yahoo.com - February 5 at 10:00 AM
News IconCoLucid Pharmaceuticals, Inc. (CLCD) Recent Analyst Updates - Risers & Fallers (NASDAQ:CLCD)
www.risersandfallers.com - February 2 at 1:03 PM
finance.yahoo.com logoCoLucid Pharmaceuticals to Present Corporate Overview at the BIO CEO & Investor Conference (NASDAQ:CLCD)
finance.yahoo.com - February 2 at 8:00 AM

Social

CoLucid Pharmaceuticals (NASDAQ:CLCD) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff